ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer

Pancreatic cancer is one of the most malignant tumors, with rapid metastasis, high mortality rate, and difficult early screening. Currently, gemcitabine is a first-line drug for pancreatic cancer patients, but its clinical effect is limited due to drug resistance. It is particularly important to fur...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Aging (Albany, NY.) NY.), 2022-10, Vol.14 (19), p.7941-7958
Hauptverfasser:	Yu, Pian, Luo, Shifu, Cai, Jiaxin, Li, Jie, Peng, Cong
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminopeptidases - pharmacology Aminopeptidases - therapeutic use Biomarkers Cell Line, Tumor Drug Resistance, Neoplasm - genetics Gemcitabine Humans Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - metabolism Research Paper RNA, Messenger
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!